# Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

Source: https://onco.cc/trials/nct04901741/  
OnCo record `nct04901741` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab in pancreatic cancer, run by TME Pharma AG, not yet recruiting.

## Summary

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer is a phase 2, interventional study registered as NCT04901741 by TME Pharma AG, with a registry enrolment figure of 60 participants, started 2026-01 and due to reach its primary completion in 2028-03. Interventions recorded: Olaptesed pegol; Pembrolizumab. Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Go/no-go decision for a randomized expansion study. Pancreatic eligibility wording from the registry: "* Patient with histologically or cytologically confirmed primary metastatic adenocarcinoma of the pancreas, who". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: OPTIMUS
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04901741
- Phase: 2
- Setting: An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer Patients
- Sponsor: TME Pharma AG
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04901741: https://clinicaltrials.gov/study/NCT04901741

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04901741.json